13/05/2026
PCOS will soon have a new name — PMOS - Polyendocrine Metabolic Ovarian Syndrome
And honestly? The change makes a lot of sense.
For years, the name Polycystic O***y Syndrome has caused confusion for both women and healthcare professionals. Many women with PCOS don’t actually have ovarian cysts, while others are told they “can’t have PCOS” because cysts weren’t seen on ultrasound.
But this condition has always been about far more than the ovaries.
Researchers and international experts are now proposing the name Polyendocrine Metabolic Ovarian Syndrome (PMOS) to better reflect what’s really happening in the body.
Because this condition is not just reproductive.
It’s metabolic.
Hormonal.
Inflammatory.
Whole-body.
PMOS recognises the wider picture:
• insulin resistance and blood sugar dysregulation
• androgen excess and hormonal imbalance
• inflammation
• ovulation dysfunction
• gut and metabolic health changes
• increased long-term risks for fertility, weight gain, mood disorders, cardiovascular disease, and type 2 diabetes
The proposed name change followed one of the largest global consensus processes ever undertaken for this condition, involving more than 14,000 patients and healthcare professionals worldwide.
And considering PMOS affects around 1 in 8 women, this matters.
Why?
Because names shape understanding.
When a condition is poorly named, it can:
• delay diagnosis
• minimise symptoms
• increase stigma
• narrow treatment approaches
• reduce research and funding focus
Many women have spent years being told:
“Your scans are normal.”
“Just lose weight.”
“You’re too young to worry.”
“It’s only a fertility issue.”
But PMOS acknowledges what many women have experienced all along:
this is a complex endocrine and metabolic condition that deserves a more accurate framework.
The name change will slowly occur over three years, and while the change happens, let’s keep the conversation going — because women deserve better understanding, earlier support, and more comprehensive care.